Cargando…
Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding
The non-vitamin K antagonist oral anticoagulants (NOACs) have considerably changed clinical practice and are increasingly being used as an alternative to vitamin K antagonists (VKAs) for 3 main reasons: 1) an improved benefit-risk ratio (in particular lower rates of intracranial bleeding), 2) a more...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290726/ https://www.ncbi.nlm.nih.gov/pubmed/30128955 http://dx.doi.org/10.1007/s00508-018-1381-5 |
_version_ | 1783380145868898304 |
---|---|
author | Gremmel, Thomas Niessner, Alexander Domanovits, Hans Frossard, Martin Sengölge, Gürkan Steinlechner, Barbara Sycha, Thomas Wolzt, Michael Pabinger, Ingrid |
author_facet | Gremmel, Thomas Niessner, Alexander Domanovits, Hans Frossard, Martin Sengölge, Gürkan Steinlechner, Barbara Sycha, Thomas Wolzt, Michael Pabinger, Ingrid |
author_sort | Gremmel, Thomas |
collection | PubMed |
description | The non-vitamin K antagonist oral anticoagulants (NOACs) have considerably changed clinical practice and are increasingly being used as an alternative to vitamin K antagonists (VKAs) for 3 main reasons: 1) an improved benefit-risk ratio (in particular lower rates of intracranial bleeding), 2) a more predictable effect without the need for routine monitoring, and 3) fewer food and drug interactions compared with VKAs. Currently, there are four NOACs available: the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, and the thrombin inhibitor dabigatran. This consensus paper reviews the properties and usage of NOACs in a number of high-risk patient populations, such as patients with chronic kidney disease, patients ≥80 years of age and others and provides guidance for the use of NOACs in patients at risk of bleeding. |
format | Online Article Text |
id | pubmed-6290726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer Vienna |
record_format | MEDLINE/PubMed |
spelling | pubmed-62907262018-12-27 Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding Gremmel, Thomas Niessner, Alexander Domanovits, Hans Frossard, Martin Sengölge, Gürkan Steinlechner, Barbara Sycha, Thomas Wolzt, Michael Pabinger, Ingrid Wien Klin Wochenschr Consensus Report The non-vitamin K antagonist oral anticoagulants (NOACs) have considerably changed clinical practice and are increasingly being used as an alternative to vitamin K antagonists (VKAs) for 3 main reasons: 1) an improved benefit-risk ratio (in particular lower rates of intracranial bleeding), 2) a more predictable effect without the need for routine monitoring, and 3) fewer food and drug interactions compared with VKAs. Currently, there are four NOACs available: the factor Xa inhibitors apixaban, edoxaban, and rivaroxaban, and the thrombin inhibitor dabigatran. This consensus paper reviews the properties and usage of NOACs in a number of high-risk patient populations, such as patients with chronic kidney disease, patients ≥80 years of age and others and provides guidance for the use of NOACs in patients at risk of bleeding. Springer Vienna 2018-08-20 2018 /pmc/articles/PMC6290726/ /pubmed/30128955 http://dx.doi.org/10.1007/s00508-018-1381-5 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Consensus Report Gremmel, Thomas Niessner, Alexander Domanovits, Hans Frossard, Martin Sengölge, Gürkan Steinlechner, Barbara Sycha, Thomas Wolzt, Michael Pabinger, Ingrid Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding |
title | Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding |
title_full | Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding |
title_fullStr | Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding |
title_full_unstemmed | Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding |
title_short | Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding |
title_sort | non-vitamin k antagonist oral anticoagulants in patients with an increased risk of bleeding |
topic | Consensus Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290726/ https://www.ncbi.nlm.nih.gov/pubmed/30128955 http://dx.doi.org/10.1007/s00508-018-1381-5 |
work_keys_str_mv | AT gremmelthomas nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT niessneralexander nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT domanovitshans nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT frossardmartin nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT sengolgegurkan nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT steinlechnerbarbara nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT sychathomas nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT wolztmichael nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding AT pabingeringrid nonvitaminkantagonistoralanticoagulantsinpatientswithanincreasedriskofbleeding |